268 related articles for article (PubMed ID: 10991994)
1. Mibefradil block of cloned T-type calcium channels.
Martin RL; Lee JH; Cribbs LL; Perez-Reyes E; Hanck DA
J Pharmacol Exp Ther; 2000 Oct; 295(1):302-8. PubMed ID: 10991994
[TBL] [Abstract][Full Text] [Related]
2. An inner pore residue (Asn406) in the Nav1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels.
McNulty MM; Kyle JW; Lipkind GM; Hanck DA
Mol Pharmacol; 2006 Nov; 70(5):1514-23. PubMed ID: 16885209
[TBL] [Abstract][Full Text] [Related]
3. Effect of mibefradil on voltage-dependent gating and kinetics of T-type Ca(2+) channels in cortisol-secreting cells.
Gomora JC; Xu L; Enyeart JA; Enyeart JJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):96-103. PubMed ID: 10604935
[TBL] [Abstract][Full Text] [Related]
4. A mibefradil metabolite is a potent intracellular blocker of L-type Ca(2+) currents in pancreatic beta-cells.
Wu S; Zhang M; Vest PA; Bhattacharjee A; Liu L; Li M
J Pharmacol Exp Ther; 2000 Mar; 292(3):939-43. PubMed ID: 10688607
[TBL] [Abstract][Full Text] [Related]
5. Effect of mibefradil on sodium and calcium currents.
Strege PR; Bernard CE; Ou Y; Gibbons SJ; Farrugia G
Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G249-53. PubMed ID: 15790762
[TBL] [Abstract][Full Text] [Related]
6. Voltage-dependent calcium channels.
Lacinová L
Gen Physiol Biophys; 2005 Jun; 24 Suppl 1():1-78. PubMed ID: 16096350
[TBL] [Abstract][Full Text] [Related]
7. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
Lee TS; Kaku T; Takebayashi S; Uchino T; Miyamoto S; Hadama T; Perez-Reyes E; Ono K
Pharmacology; 2006; 78(1):11-20. PubMed ID: 16899990
[TBL] [Abstract][Full Text] [Related]
8. State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel.
Freeze BS; McNulty MM; Hanck DA
Mol Pharmacol; 2006 Aug; 70(2):718-26. PubMed ID: 16699084
[TBL] [Abstract][Full Text] [Related]
9. High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.
Eller P; Berjukov S; Wanner S; Huber I; Hering S; Knaus HG; Toth G; Kimball SD; Striessnig J
Br J Pharmacol; 2000 Jun; 130(3):669-77. PubMed ID: 10821797
[TBL] [Abstract][Full Text] [Related]
10. Influence of T-type Ca2+ (mibefradil) and Cl- (indanyloxyacetic acid 94) channel antagonists on alpha1-adrenoceptor mediated contractions in rat aorta.
Duggan JA; Tabrizchi R
Can J Physiol Pharmacol; 2000 Sep; 78(9):714-20. PubMed ID: 11007534
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel T-type calcium channel blockers.
Choi JY; Seo HN; Lee MJ; Park SJ; Park SJ; Jeon JY; Kang JH; Pae AN; Rhim H; Lee JY
Bioorg Med Chem Lett; 2007 Jan; 17(2):471-5. PubMed ID: 17064894
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of in vitro contractions of human myometrium by mibefradil, a T-type calcium channel blocker: support for a model using excitation-contraction coupling, and autocrine and paracrine signaling mechanisms.
Young RC; Zhang P
J Soc Gynecol Investig; 2005 May; 12(4):e7-12. PubMed ID: 15866110
[TBL] [Abstract][Full Text] [Related]
13. Nickel block of three cloned T-type calcium channels: low concentrations selectively block alpha1H.
Lee JH; Gomora JC; Cribbs LL; Perez-Reyes E
Biophys J; 1999 Dec; 77(6):3034-42. PubMed ID: 10585925
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2.
Moosmang S; Haider N; Brüderl B; Welling A; Hofmann F
Circ Res; 2006 Jan; 98(1):105-10. PubMed ID: 16306443
[TBL] [Abstract][Full Text] [Related]
15. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Baylis C; Qiu C; Engels K
Am J Kidney Dis; 2001 Dec; 38(6):1292-7. PubMed ID: 11728963
[TBL] [Abstract][Full Text] [Related]
16. The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels.
Mehrke G; Zong XG; Flockerzi V; Hofmann F
J Pharmacol Exp Ther; 1994 Dec; 271(3):1483-8. PubMed ID: 7996461
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers.
Lee HK; Lee YS; Roh EJ; Rhim H; Lee JY; Shin KJ
Bioorg Med Chem Lett; 2008 Aug; 18(15):4424-7. PubMed ID: 18625556
[TBL] [Abstract][Full Text] [Related]
18. Ca2+-agonistic effect of a T-type Ca-channel blocker mibefradil (Ro 40-5967).
Avdonin PV; Buhler FR; Tkachuk VA
Membr Cell Biol; 2000; 13(5):645-55. PubMed ID: 10987388
[TBL] [Abstract][Full Text] [Related]
19. Effects of the T-type calcium channel blockade with oral mibefradil on the electrophysiologic properties of the human heart.
Mádle A; Linhartová K; Koza J
Med Sci Monit; 2001; 7(1):74-7. PubMed ID: 11208497
[TBL] [Abstract][Full Text] [Related]
20. Action of mibefradil and lacidipine on the isolated human anterior tibial artery.
Martinuc J; Drevensek G; Budihna MV
Pflugers Arch; 2000; 440(5 Suppl):R147-8. PubMed ID: 11005648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
